NDAORALTABLET, EXTENDED RELEASE
Approved
Mar 2013
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
DESVENLAFAXINE (desvenlafaxine) by Hikma is norepinephrine uptake inhibitors [moa]. Approved for major depressive disorder, vasomotor symptoms. First approved in 2013.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Desvenlafaxine is an oral extended-release SNRI approved in 2013 for major depressive disorder and vasomotor symptoms. It works by inhibiting the reuptake of serotonin and norepinephrine in the central nervous system. The drug is the active metabolite of venlafaxine, offering an alternative mechanism to selective serotonin reuptake inhibitors.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30%), indicating established market position but limited growth trajectory for commercial team expansion.
Mechanism of Action
Norepinephrine Uptake Inhibitors
Pharmacologic Class:
Serotonin and Norepinephrine Reuptake Inhibitor
Indications (2)
Worked on DESVENLAFAXINE at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.